Scholars Central

Conference abstractPublished 30 Jan 2017

Molecular mechanism investigation of a novel Ruthenium (II) complex inhibits proliferation of human esophageal squamous cell carcinoma

Authors: Jianguo Lin, Liubin Guo, Gaochao Lv, Ling Qiu

Jiangsu Institute of Nuclear Medicine, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

High toxicity acquired resistance and serious side effects, prompting the search for novel compounds for cancer treatment. Recently, a Ruthenium (II) complex [Ru (p-cymene)(L)Cl2] (L = 1,3-bis(4-(tert-butyl)benzyl)-1H-imidazol-3-ium chloride) , which named L-4, has been synthesized and characterized. The purpose of this study was to investigate the effects of L-4 against human esophageal squamous carcinoma (ESCC) cell line EC109. Different methods to determine the apoptotic pathways triggered by L-4 in EC109 cells were investigated by using flow cytometry, Hoechst 33258 staining, Caspases activation, mitochondria functioning, generation of reactive oxygen species (ROS) and western-blotting techniques. Results showed that a dose- and time-dependent reduction occurred in cell viability after exposure to L-4 in EC109 cells. The flow cytometry analysis showed that L-4 induced cell cycle arrest at G2/M phase in EC109 cells, concomitant to p53 and p21 upregulation and Cyclin D1 down-regulation. L-4 also induced ROS-dependent and mitochondria-mediated apoptosis in EC109 cells by targeting the glutathione reductase, leading to generation of ROS, Ca2+ overloading, increase of Bax/Bcl-2 ratio, loss of MMP, release of cytochrome c into the cytosol, and then activation of Caspase-3/-9. Whereas, ROS scavengers, N-acetyl- L-cysteine, significantly attenuated the effects of L-4 on reduction of cell viabilities, activity of GR, generation of ROS, loss of MMP, the dysfunction of mitochondria and induction of apoptosis. The preliminary results suggest that the Ruthenium (II) complex, L-4, inhibits EC109 cells proliferation via blocking cell cycle progression and inducing ROS-dependent and mitochondria-mediated apoptosis, and deserves further investigation as a new chemotherapeutic strategy for patients with esophageal cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Jianguo Lin”
  • BylineArticles whose byline prints “Liubin Guo”
  • BylineArticles whose byline prints “Gaochao Lv”
  • BylineArticles whose byline prints “Ling Qiu”